Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine for preventing and/or treating allergic asthma

A technology for allergic asthma and vaccines, applied in allergic diseases, respiratory diseases, allergen antigen components, etc., can solve problems such as Candida albicans infection, hypertension, etc.

Inactive Publication Date: 2013-04-10
CHINA AGRI UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, long-term oral administration of hormones may cause side effects such as obesity, osteoporosis, and high blood pressure; inhalation of hormone sprays may cause Candida albicans infection in the mouth and throat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine for preventing and/or treating allergic asthma
  • Vaccine for preventing and/or treating allergic asthma
  • Vaccine for preventing and/or treating allergic asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Embodiment 1, pep323 and pD323 joint immunosuppressive asthma

[0047] experimental method

[0048] Experimental animals: female BALB / c mice (8-10 weeks old) were purchased from the Institute of Experimental Animals, Chinese Academy of Medical Sciences. DO11.10 mice (8-10 weeks old) were purchased from Shanghai Slack Experimental Animal Co., Ltd. (SLAC).

[0049] Neutralizing antibodies: various neutralizing antibodies used in the experiment, including anti-CD25, anti-CD4, anti-IL-10, anti-IFN-γ, anti-TGF-β and anti-IL-4, anti-IL -2 were obtained from hybridoma cells purchased from ATCC (Manassas, VA, USA).

[0050] 1. Experimental method

[0051] 1. Asthma model induction: OVA (Sigma, USA; 1 mg / ml dissolved in PBS) was mixed with an equal volume of 10% aluminum salt (Sigma, USA) as an allergic antigen, and oscillated for 2 hours at room temperature. After centrifugation at 750×g for 5 min, the supernatant was discarded and the OVA / aluminum complex was resuspended w...

Embodiment 2

[0092] Example 2, Der p1 protein and pVAX-Der p1 combined immunosuppressive asthma

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a prophylactic and / or therapeutic vaccine against allergic asthma. The mixture of protein antigen or epitope peptide triggering allergic asthma, and recombinant eukaryotic vector expressing said protein antigen or epitope peptide is as active ingredient.

Description

technical field [0001] The invention relates to a vaccine for preventing and / or treating allergic asthma. Background technique [0002] Asthma (Asthma) is a chronic airway inflammation involving the participation of various cells such as mast cells, eosinophils and T lymphocytes. The pathogenesis of asthma is mainly type I hypersensitivity (anaphylaxis). [0003] Allergic asthma is more common than childhood onset, and patients often have atopic constitutions that are allergic to certain substances, such as inhaling cold air, pollen, dust mites, etc.; eating fish, shrimp, milk, etc.; or being exposed to certain drugs, such as penicillin. When these allergens enter the patient's body, through a series of reactions, mast cells or basophils release sensitizing active substances, which act on the bronchi, causing extensive narrowing of the small airways, and symptoms of wheezing occur. If not treated in time, asthma Can be fatal. [0004] When the allergen enters the body, it...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/35A61P11/06A61P37/08
CPCA61K39/35A61P11/06A61P37/08
Inventor 王宾金华利靳津康友敏
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com